LB Pharmaceuticals Inc (LBRX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

LB Pharmaceuticals Inc (LBRX) closed at USD 34.00 on 2026-10-14, a change of +105.2 % over the past year, with a market capitalization of USD 1.18B.

LB Pharmaceuticals Inc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

LB Pharmaceuticals Inc key figures

Previous close

USD 34.00 (2026-10-14)

1-year change

+105.2 %

Market cap

USD 1.18B

Enterprise value

USD 861.02M

P/E ratio (trailing)

366.90

P/E ratio (forward)

-7.15

EPS (trailing)

0.10

EPS (forward)

-5.13

PEG ratio

n/a

Price to book

3.17

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

17.30

Employees

49

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About LB Pharmaceuticals Inc

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for LB Pharmaceuticals Inc and compare it with other stocks.